189 related articles for article (PubMed ID: 27939613)
21. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Anfuso B; Tiribelli C; Adorini L; Rosso N
Sci Rep; 2020 Feb; 10(1):1699. PubMed ID: 32015483
[TBL] [Abstract][Full Text] [Related]
22. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
[TBL] [Abstract][Full Text] [Related]
23. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
24. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
[TBL] [Abstract][Full Text] [Related]
25. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
[TBL] [Abstract][Full Text] [Related]
26. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
27. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
[TBL] [Abstract][Full Text] [Related]
28. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
[TBL] [Abstract][Full Text] [Related]
29. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
30. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes.
Zhang Y; Jackson JP; St Claire RL; Freeman K; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805978
[TBL] [Abstract][Full Text] [Related]
31. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
[TBL] [Abstract][Full Text] [Related]
32. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A
Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Alkhouri N; LaCerte C; Edwards J; Poordad F; Lawitz E; Lee L; Karan S; Sawhney S; Erickson M; MacConell L; Zaru L; Chen J; Campagna J
Liver Int; 2024 Apr; 44(4):966-978. PubMed ID: 38293761
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
36. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP; Steinman L
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
[TBL] [Abstract][Full Text] [Related]
37. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Hameed B; Terrault NA; Gill RM; Loomba R; Chalasani N; Hoofnagle JH; Van Natta ML;
Aliment Pharmacol Ther; 2018 Mar; 47(5):645-656. PubMed ID: 29333665
[TBL] [Abstract][Full Text] [Related]
38. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
39. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Shah RA; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
